Africa: Continent of genome contrasts with implications for biomedical research and health  by Ramsay, Michèle
FEBS Letters 586 (2012) 2813–2819journal homepage: www.FEBSLetters .orgReview
Africa: Continent of genome contrasts with implications for biomedical
research and health
Michèle Ramsay
Division of Human Genetics, National Health Laboratory Service and School of Pathology, Faculty of Health Sciences and the Sydney Brenner Institute for Molecular
Bioscience, University of the Witwatersrand, Johannesburg, South Africaa r t i c l e i n f o
Article history:
Received 21 July 2012
Accepted 23 July 2012
Available online 31 July 2012







Health transition0014-5793  2012 Published by Elsevier B.V. on beha
http://dx.doi.org/10.1016/j.febslet.2012.07.061
E-mail address: Michele.Ramsay@nhls.ac.zaa b s t r a c t
The genomic architecture of African populations is poorly understood and there is considerable var-
iation between ethno-linguistic groups. Genome-wide approaches have been extensively applied to
search for genetic associations to complex traits in Europeans, but rarely in Africans. This is largely
attributed to lower levels of funding, poor infrastructure and public health systems, and to the small
pool of trained scientists. High levels of genetic variation and underlying population structure in
Africans present signiﬁcant challenges, but lower levels of linkage disequilibrium provide an oppor-
tunity for more effective localisation of causal variants. High throughput technologies, including
dense genotyping arrays, genome sequencing and epigenome studies, together with plummeting
costs, are making research more affordable, even for African scientists. Understanding the interac-
tions between genome structure and environmental inﬂuences is essential to interpreting their con-
tributions to the increase in infectious diseases and non-communicable diseases, exacerbated by
adverse environments and lifestyle choices. The unique genome dynamics in African populations
have an important role to play in understanding human health and susceptibility to disease.
 2012 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.Open access under CC BY-NC-ND license.1. The origin of modern man in Africa
Recent studies on genome-wide human genetic variation in
many populations have provided substantial support for a Recent
African Origin of anatomically modern humans. This is endorsed
by the ﬁnding that most genetic variation is observed among Afri-
can populations and only a subset of this diversity is found in non-
Africans. Some of the questions that are now debated include:
Where in Africa did non-Africans migrate from? When did they
leave the continent? How often did an exodus occur? Fascinating
patterns are emerging from the highly complex population
structure among Africans and traces of population migration,
admixture, and ﬂuctuations in population size, either through pop-
ulation bottlenecks or rapid expansions, are discernable.
Studies to shed light on population origins and admixture have
used speciﬁc DNA marker variants for different purposes. Maternal
lineages are studied through mitochondrial DNA (mtDNA) varia-
tion and paternal lineages through Y chromosome data. A vast lit-
erature describes many interesting studies tracing the origins of
contemporary populations using mtDNA variation, but I will share
only a few continent-wide studies. Whole mtDNA sequencing in a
group of Africans suggest that Khoisan lineages of sub-Saharan
Africa diverged from the rest of the populations worldwide be-
tween 90000 and 150000 years before present (ybp). These datalf of the Federation of European Bfurther support a migration out of Africa between 60000 and
70000 ybp and suggest that it is most likely attributable to a single
wave of dispersal [1]. Another dataset of 224 complete mtDNA
genomes was used to trace the origin and history of four major
haplogroups (L0–L3), and to estimate the timing of major popula-
tion expansions on the continent. This study provided strong sup-
port for a major expansion within Africa before the subsequent
expansion out of Africa [2]. In a study based on the sequencing
of 200 kb of the male-speciﬁc region of the Y chromosome, the pat-
terns of variation were used to estimate the origin of the human Y
chromosome as 142000 ybp and the analysis of African-speciﬁc
clades conﬁrms the early origin of modern humans in Africa [3].
Autosomal markers have also been used extensively to study
population afﬁnities. A study based on genotyping 1327 microsat-
ellite markers and insertions/deletions in a cohort of 2432 individ-
uals from 121 geographically diverse African populations,
identiﬁed 14 ancestral population clusters [4]. High density typing
of a million SNPs in 235 individuals from 10 Ethiopian populations
and two neighbouring populations in South Sudan and Somalia, re-
vealed both African and non-African patterns of diversity reﬂecting
their ancient history in Africa and recent back migration, which is
estimated to have occurred about three thousand years ago [5].
There was a correlation between genome structure and linguistic
afﬁliation within the Ethiopian populations emphasizing the need
for studying ethno-linguistic groups rather than selecting groups
based on recent political boundaries.Open access under CC BY-NC-ND license. iochemical Societies.
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estimate more precise dates for the split between African and
non-African populations. Based on a study of ﬁve whole genomes
(three African and two non-African) Gronau et al. estimated a rel-
atively recent split between 38000 and 64000ybp [6], whereas an-
other study also based on whole genome sequencing estimated it
at 60000–80000ybp, using a different approach [7].
The contrasting environmental niches across the African conti-
nent, from tropical forests in central Africa and arid conditions
with food scarcity both towards the north and south, as well as
dramatic cultural advances during the past 100000 years, have
contributed to the regional differences in adaptation. The geo-
graphic isolation and vacillating population sizes, as a result of
population bottlenecks and rapid expansions, and random genetic
drift, have further fuelled the genetic diversity across the
continent.
There is broad consensus on the exodus from Africa between
50000 and 80000 years ago. As mentioned above, the populations
have since been shaped by a combination of demographic and evo-
lutionary forces which have contributed to the patterns of genetic
variation we observe in populations today. Our challenge is to
work towards designing analytical tools that can examine popula-
tion differences and distinguish these forces, while also consider-
ing random genetic drift. The demographic processes reﬂect
historical events such as migrations, conﬂicts and admixture,
which in turn affect population size, and the locus speciﬁc evolu-
tionary forces include new mutations, natural selection (including
selection for advantageous phenotypes in new environments and
purifying selection), gene conversion and recombination.
2. Genome-wide human genetic variation
The African continent has consistently been under-represented
in genome-wide studies of genetic diversity and disease associa-
tion [8] despite the pivotal role that Africa has played in the evolu-
tion of humankind. However, whole genome sequencing is now
becoming more widely practiced, accessible and increasingly
affordable, which provides unique opportunities for improving res-
olution of genomic data when examining genetic susceptibilities to
disease and in studying human evolution.
The ﬁrst African whole genome sequence, that of an unidenti-
ﬁed Nigerian, appeared in the public domain in 2008 [9] and the
ﬁrst southern African genomes, published in 2010, included a rep-
resentative of the Bantu-speakers, Archbishop Emeritus Desmond
Tutu who was happy to have his name made public, and a San indi-
vidual from Namibia [10]. The sequencing of an additional three
San exomes (coding regions of the genome) from individuals each
representing a different linguistic sub-group and whose clan lives
in a very restricted geographic niche, revealed that they were
genetically more different from one another than one would ex-
pect, on average, between a European and Asian [10]. A study on
over half a million SNPs in individuals from several hunter-gath-
erer populations in Africa conﬁrmed that they are highly differen-
tiated and Henn et al. argue in favour of a southern African, rather
than east African origin for modern humans [11].
De novo sequencing of selected chromosomal regions in 692
unrelated individuals revealed that the discovery rate of novel se-
quence variants is considerably higher in African populations (rep-
resented by one Nigerian and two distinct Kenyan populations),
than in European (resident in North America and in Europe) and
Asian populations (Japanese and Chinese populations) [12]. Ran-
dom sampling was done in different populations and compared
across populations to examine the ability of one population to rep-
resent or predict genetic diversity in another. With regard to mark-
ers that were polymorphic (minor allele frequency >0.01), the
African populations had genetic variants that were more likely tobe present in non-Africans than the other way around. However,
in conﬁrmation of the high level of population structure in Africa,
variation from one African population was not necessarily a good
predictor of the genetic variation present in another. This extensive
diversity between African populations emphasises the need to ex-
plore and understand the genomic architecture of individual
groups.
The 1000 Genomes Project, which aims to characterise over 95%
of variants with a minor allele frequency of 1% or higher in popu-
lations from Europe, East Asia, South Asia, West Africa and the
Americas [13] has already yielded an exceptional amount of data
and additional populations from other regions of the world are
being sequenced. In the publication of the ﬁrst phase in October
2010, high coverage genome sequencing in two family trios re-
vealed that single base substitution mutations arise in the germ
line at a rate of approximately 108 per base per generation. This
serves as a reminder of the constant replenishment of new muta-
tions in our collective genome, of which very few are likely to be
of functional consequence, and our relatively poor reproductive
rate suggests that most of the variants are unlikely to make it
through many generations. Low coverage sequencing of whole
genomes demonstrated that individuals from an African popula-
tion had a higher number of average variant SNP sites (a mean of
3.3 million SNPs per individual, compared to a mean of 2.9 million
SNPs in European individuals and 2.8 million SNPs in Japanese/Chi-
nese). In Africans, 47% of all SNPs detected were novel and not rep-
resented in data-bases at the time of analysis. In the European
population, 33% of SNPs were novel and in the Asian populations
28% were novel. These data emphasise the rich source of genetic
variation in an African population, and auger well for the discovery
of much more variation when additional African populations are
sequenced. Naturally, as the databases grow, there will be a dimin-
ishing return of novel SNPs. However, such studies will lead to an
increasing number of rare SNPs being identiﬁed and to a better
understanding of global genetic variation.
The ﬁeld of genomic medicine is premised on the role of ances-
tral variation in disease processes [14]. It is important to under-
stand how differences in allele frequencies may affect the utility
of a variant in a speciﬁc population or how regional chromosomal
contexts may change the functional impact of a variant allele. One
of the best studied pharmacogenetic examples is the FDA approved
testing for speciﬁc genetic variants to inform warfarin dose during
treatment. The CYP2C9 SNP (rs1799853) is not polymorphic in Afri-
cans and two VKORC1 SNPs (rs17708472 and rs9934438) have low
variant allele frequencies, limiting their potential clinical relevance
in African populations [15]. As another example, patients with
metastatic colorectal cancer and who are homozygous for the
UGT1A1⁄28 allele are at increased risk for hematologic toxicity
when treated with irinotecan [16]. This variant is used in a screen-
ing test for at-risk patients. In Europeans, homozygotes represent
about 10% of the population, whereas allele frequencies in Africans
indicate that up to 1 in 4 patients will be homozygous for this func-
tional allele [17]. The test therefore is very relevant for African pa-
tients since many individuals are likely to present with toxicity for
irinotecan.
Regional chromosomal effects for the sickle cell mutation are
well known to modulate the severity of disease in sickle cell pa-
tients. As shown in Fig. 1, Africa has a disproportionate burden
from malaria infection and one of the consequences has been
selection for a high frequency of the sickle cell mutation because
of a heterozygote survival advantage. However, an unfortunate
outcome has been many babies born in these regions as homozy-
gotes with sickle cell disease. Disease severity is correlated with
different haplotypes in the HBB (beta globin) gene cluster and they,
in turn, are associated with different levels of gamma globin pro-
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Fig. 1. The three maps show the disproportionate burden of HIV infection, malaria and tuberculosis (TB) in Africa according to territory size. HIV is represented by the
proportion of all people aged 15–49 years infected with HIV. TB is the proportion of TB cases found in a region and malaria the proportion of a people living with malaria
worldwide. The maps are reproduced with permission from: www.worldmapper.org - SASI Research Group (University of Shefﬁeld) and Mark Newman (University of
Michigan). The pie charts show the causes of deaths in Africa and Europe compared with the world average (based onWorld Health Organizational Causes of death, 2008, data
http://www.who.int/evidence/bod) as modiﬁed from Ramsay et al. [8].
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associated with the Senegal and Saudi-Indian HBB haplotypes.
Efforts are being made to develop therapies that can ameliorate
disease severity by stimulating higher levels of gamma globin
expression in sickle cell patients.
The application of genetic/genomic data in a clinical setting
needs to be analysed and interpreted in the context of ethnicity
to understand its potential signiﬁcance [14]. Careful attention
should, furthermore, be paid in resource poor settings to fully
understand the clinical validity of the test in a speciﬁc population,
before its utility can be assessed. This can be challenging, as it is
likely that the relevant research has yet to be conducted in the
population of interest.
3. Unequal burden of adverse environments
The recent two to three thousand years has been characterised
by increased population migrations, likely triggered by milder cli-
matic conditions and the domestication of animals and agricultural
crops. In addition to their own genes, languages and cultural prac-
tices, migrating people have taken with them their microbiota and
pathogens. This led to population size ﬂuctuations, admixture,
replacement, assimilation and many other population dynamics.
Unfortunately the importation of pathogens and their introduction
into populations with no previous exposure, led to infectious dis-
ease epidemics where a large proportion of susceptible individuals
died. This left behind a population enriched for protective allelic
variants.
Regional disparities in the burden of infectious diseases reﬂect
both immune adaptation due to prior exposure and genetic suscep-
tibility or resistance. Protective alleles may increase in a popula-
tion due to natural selection, but this can take many decades of
constant and high exposure. In Fig. 1, the disproportionate burden
of HIV infection, malaria and tuberculosis in Africa is illustrated.
The ﬁgure also shows continental averaged deaths due to infec-
tious diseases, relative to other causes. It should be noted thatthe granularity across countries is not well illustrated. In a propor-
tion of African, and other developing countries, an increase in non-
communicable diseases is being exacerbated by adverse lifestyle
choices.
Many African counties have experienced periods of severe
famine and political upheaval in their recent history, worsening
their health outcomes. Despite the signiﬁcant health challenges,
Africans remain understudied, especially in terms of the genetic
and molecular aetiology of disease.
4. Parallel processes operating in population health and
common complex diseases
Health is inﬂuenced by many factors and recent advances in
molecular techniques and our capability to do high-throughput
experiments generating massive amounts of data, is enabling us
to study disease processes at increasing levels of complexity. Ge-
netic variation remains relatively constant over decades, but the
environment can change dramatically in terms of diet and exercise,
in a relatively short time. The parallel and interlinked processes
that impact health include genomic architecture (based on genetic
variation and linkage disequilibrium), socioeconomic status, the
microbiome, and the environmental impact on the epigenome that
affects gene expression through complex processes. Few research
studies incorporate all these elements in their full complexity
when attempting to identify predictors of future patterns of dis-
ease. Models perhaps include too many weakly supported assump-
tions to calculate a reasonable outcome. A high level approach is
outlined in Fig. 2 and would require vast amounts of funding and
data generation to explore fully, especially in African populations
that have been neglected in the biotechnology revolution. We need
a clearer picture of associations, systems biology and an under-
standing of potential causality, before such an approach can be
meaningfully implemented.
Genome-wide association studies (GWASs) have dominated the
landscape of research aimed at identifying common genetic
Differential gene 
expression
Fig. 2. A complex set of interdependent and parallel processes govern health and susceptibility to disease. They include the role and function of genetic variation (central
panel), epigenetic remodelling (left panel) and the microbiome (right panel), with the latter two signiﬁcantly affected by the environment and acting as mediators of the
phenotype. The nuclear and mitochondrial DNA is determined at conception and remains essentially constant throughout life. Differential gene expression is a key feature of
cell differentiation and is determined by epigenetic processes and RNA interference, which are essential for normal development. The ﬂuid epigenome differs between cell
types, with age and in response to environmental triggers, but is also partly inﬂuenced by genetic variation.
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from the Wellcome Trust Case Control Consortium identiﬁed 24
independent association signals robustly associated with seven
disease phenotypes, including type 2 diabetes, hypertension and
rheumatoid arthritis [19]. Over the past decade many GWAS stud-
ies have been published and meta-analyses have been done to
increase sample size and search for additional associations. How-
ever, in general, these explain a relatively small proportion of the
inherited variation of the trait. For example, obesity is estimated
to be between 40 and 70% heritable, yet positive associations in
GWAS studies and meta-analyses have revealed well over a dozen
robust associations that explain less than 2% of the heritable vari-
ation [20,21]. A recent meta-analysis of 17 GWASs on bone mineral
density (BMD) identiﬁed 57 BMD associated loci and 14 loci asso-
ciated with the risk for bone fracture [22]. They conﬁrmed the role
of several pathways in bone mineralisation but the associated loci
explain only a fraction of the genetically determined variation for
the trait. One of the notable successes of GWAS in explaining her-
itability has been for the phenotypic trait of height. In a meta-anal-
ysis, 114223 individuals from 47 studies and six ethnicities were
studied, and 64 loci associated with height were identiﬁed,
explaining a substantial proportion of the heritability [23].
Only a hand full of GWA studies have been conducted in non-
admixed African populations. The challenges of doing such studies
in Africans are described by Teo et al.[24] and emphasise African
population diversity and structure and the notable advantages of
using the low linkage disequilibrium to narrow down causal vari-
ants. A GWA study was conducted to identify genetic determinants
for susceptibility to malaria in West African children, highlightingthe role of the sickle cell mutation [25]. They illustrated the need
to adjust for population stratiﬁcation in order to obtain enhanced
signals of association. Another GWA study in West Africa identi-
ﬁed a susceptibility locus for TB on chromosome 18q11.2,
although its potential biological role in TB could not be explained
[26].
The undetected heritability in most GWASs has been attributed
to many factors including the following: rare genetic variants with
larger effects, associations with as yet undiscovered variants, inap-
propriate adjustments for population structure or stratiﬁcation,
inadequate sample sizes that render the studies underpowered to
detect small effects, epigenetic variation and statistical models that
are not complex enough or entirely appropriate for the analysis of
the data generated in these studies [27–29].
More complex statistical models that take into consideration
epistasis, the interaction of multiple genetic variants in inﬂuencing
a trait, are being developed. Two recent publications have argued
that genetic interactions likely contribute to explaining signiﬁcant
heritability [29,30]. Zuk et al. make the point that the total herita-
bility of traits is often overestimated, and refers to this as ‘‘phan-
tom heritability’’. Therefore, the amount of actual variability
explained by existing associations is in fact much higher than re-
ported [29]. In addition, interactions between variants are usually
not taken into consideration. Stahl et al. developed a method based
on polygenic risk scores developed through Bayesian inference
analysis and applied it to rheumatoid arthritis, where they esti-
mate that thousands of SNPs from existing studies together explain
a further 20% of the unexplained disease risk [30]. They also
applied this method to celiac disease, cardiac disease and type 2
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could explain signiﬁcant additional disease risk.
Gene expression is regulated by gene transcription and post-
transcriptional processes. Epigenetic markings on both the DNA
and the histones work synergistically to inﬂuence chromatin struc-
ture, which in turn inﬂuences rates of transcription. Since differen-
tial gene transcription is the hall-mark of cellular differentiation, it
is not unexpected that epigenetic patterns, including differentially
methylated DNA regions (DMRs), show tissue speciﬁcity (T-DMRs),
and also signiﬁcant inter-individual differences (I-DMRs) [31]. In-
ter-individual differences are, in part, encoded in genetic variation
as shown in a study correlating gene expression data with SNP var-
iation in 77 Nigerian individuals [32]. Global and locus speciﬁc
methylation differences are also know to correlate with age, sex
and environmental exposure [33] and it remains unclear whether
DNA methylation studies using white blood cells will provide use-
ful biomarkers for disease susceptibility and end point disease [34].
A strong argument has been made for using epidemiological ap-
proaches to studying epigenetic variation and disease associations
on a population-wide scale and to use methods like Mendelian ran-
domisation to strengthen causal inference [35,36]. In the February
2012 issue of the International Journal of Epidemiology devoted to
epigenetic epidemiology, Heijmans and Mill outline the potential
pitfalls of this approach and emphasize the signiﬁcant challenges
[37].
The human microbiota on the surface of the skin, in the gastro-
intestinal tract from the oral cavity to the anus and the urogenital
tract, comprise ten times the number of somatic cells in the human
body. They have been shown to play a signiﬁcant role in several
physiological processes, including metabolism and immunity. For
example, there is a correlation between bacterial infection, broad-
spectrum antibiotic treatment early in life and increased suscepti-
bility to asthma [38]. In 2007 the Human Microbiome Project was
launched with the aim of understanding the role of the microbiota
in metabolism, normal physiological processes and predisposition
to disease [39]. To improve our knowledge, we need to understand
how stable the microbiome is throughout the life course, how sim-
ilar it is between family members and between individuals of a
community or population, whether there is a universal ‘‘core’’
microbiome and how the microbiome changes in adaptation to dif-
ferent lifestyles. Such studies may lead to new diagnostic biomark-
ers, more in depth understanding of molecular processes such as
drugmetabolism and industrial applications in the ﬁeld of food pro-
duction and biotechnology. The signiﬁcant challenges are outlined
in a recent review summarising experimental approaches and ana-
lytical tools for human microbiome studies [40].
Mouse models have provided interesting evidence that the
microbiome plays an important role in predisposition to obesity.
It was demonstrated that when themicrobiome of a genetically ob-
ese mouse (ob/ob) with mutations in the leptin gene is transferred
to a recipient, adiposity is increased, compared to recipients of the
microbiomes of lean mice [41]. The authors suggest that this is be-
cause the obesity associated gut microbiome is able to harvest en-
ergy more effectively from its diet. When considering causal
inﬂuences for the health transition, which is characterised in part
by a rapid rise in the prevalence of obesity in a population, with a
concomitant increased risk for cardiometabolic diseases including
diabetes and hypertension, the microbiome may play an important
role. However, it is also mediated through dietary changes, like in-
creased access to low cost calorie rich food, and a more sedentary
lifestyle. A study of the aetiology of obesity would not be complete
without including an investigation of the gut microbiome.
The diversity of African populations in terms of genetic
variation and structure, diet, climate and exposure to infectious
pathogens makes the continent a rich playground to study their
interaction and to investigate cause and effect. In the age of largegenomic scale research, studies on African populations present
some notable advantages; however, there are many signiﬁcant
challenges. Population structure in African populations means that
many populations need to be studied and one population could not
easily be used as a proxy for another and more extensive knowl-
edge is required to understand that relationships between
populations.
Socioeconomic factors signiﬁcantly hamper progress on the
African continent and include limited resources, a small skills base
and in general, a lack of political will to enable these studies
through a meaningful contribution from governments. A notable
contribution has been made in South Africa where the Department
of Science and Technology has begun to support a national genome
program and the Minister of Health has made a commitment to in-
crease funding for research to 2% of the health budget over the next
ten years [42].
The international community has risen to the challenge through
the establishment of the Human Heredity and Health in Africa initia-
tive [43] funded through the National Institutes of Health (USA)
and the Wellcome Trust (UK). This important development will
hopefully act as the catalyst for further investment in research to-
wards the molecular and genomic understanding of diseases com-
mon in Africa.
Genetic, genomic and epigenetic epidemiology are poised to un-
ravel important causal effects resulting in disease and morbidity,
but await multi-layered data on the same study cohorts before
comprehensive analyses can be made.5. Second wave of exploration in Africa
Just a few hundred years ago, Africa was referred to as the Dark
Continent and posed tantalising challenges to intrepid explorers of
its geography, who were also curious about the nature and lives of
its inhabitants. Many maps were constructed and books written
about the people, their languages, physical attributes and cultural
practices. However, even at this level, much detailed information
remains unrecorded.
The stories buried in the genomes of extant African populations
have made a second wave of exploration possible. New genome
studies are driven by a fascination to better understand demo-
graphic histories, but also to understand how the untapped genetic
variation of these populations interact with the environment to
synergistically and dynamically inﬂuence both health and suscep-
tibility to disease. African populations remain understudied, as
does much of the rest of the developing world [44]. Fortunately
historical records are preserved in DNA sequences and remain
accessible for investigations, generation after generation. In rare
cases the DNA record can be preserved for tens of thousands of
years and ancient DNA sequencing studies, when compared to ex-
tant human sequences, have recently brought to light the probable
intermixing of our European ancestors with Neanderthals [45,46].
Buried beneath the surface of the African continent there must be
many more genomes to explore.6. Balance of beneﬁt
Emphasis is placed on the potential beneﬁts of research, and in
biomedical research this means translation to the bedside. Basic
research, often referred to as blue skies research, does however
need to be recognised as an essential incubator for training and
for innovation in science - even in developing countries.
Beneﬁt sharing is, however, especially relevant in the context of
research in developing countries and in collaborations where one
partner stands to accrue disproportionate beneﬁt. A common
understanding and deﬁnition for beneﬁt sharing has long been
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oped a working deﬁnition which speaks to the legal, ethical, philo-
sophical and practical aspects of beneﬁt sharing, as follows:
‘‘Beneﬁt sharing is the action of giving a portion of advantages/proﬁts
derived from the use of human genetic resources to the resource pro-
viders to achieve justice in exchange, with a particular emphasis on
the clear provision of beneﬁts to those who may lack reasonable access
to resulting healthcare products and services without providing uneth-
ical inducements.’’ This deﬁnition could be used to promote more
equitable beneﬁt sharing from genomic studies [47].
Much has been written about global health disparities and the
potential lack of impact of genomic studies on neglected diseases
in the developing world, is no exception. In an attempt to explore
the best approaches to harness genomic research to improve
health in selected regions of the world, a series of workshops iden-
tiﬁed four main categories for potential intervention: Science
(building capacity), ﬁnancial frameworks and policies, public
engagement strategies (centred around ethical issues, society and
culture), and political commitment [48]. This was echoed in a ser-
ies of studies that culminated in an excellent group of publications
in 2008, highlighting the challenges and potential factors for suc-
cess, based on an investigation of genomic studies taking place in
Mexico, India, Thailand and South Africa [49]. These areas will need
to be strengthened to enable productive and equitable collabora-
tions. In a recent commentary, Bustamante et al. highlight the
Eurocentric focus of medical genomic studies and make a plea
for a concerted effort to bolster research in diverse ethnic popula-
tions and emphasize the need for ﬁnancial support from govern-
ments and non-proﬁt organisations [44].
Health-related genomic research raises interesting ethical ques-
tions as it relies on the participation of thousands of individuals
and, in order to address questions of medical relevance, it also re-
quires signiﬁcant phenotypic data. Appropriate informed consent
can be obtained in a manner that is both fully understood by the
participant, despite the complexities of the studies, and does not
create unreasonable expectation or feelings of exploitation. It does,
however need to be done in the contexts of the different commu-
nities and their cultural framework and on a basis of mutual trust.
This cannot be done in the absence of the involvement of commu-
nity leaders and the local scientists and clinicians.
The issue of genomic sovereignty is also relevant [50]. Genomic
sovereignty has been deﬁned in different ways, but its essence re-
lates to research being done on populations in their countries of
origin with the integral involvement of their own people. This
can, of course, be interpreted in many ways but requires commit-
ment to the spirit and not only the mechanics of ethical guidelines
in health research on populations from developing countries.
7. Future Directions
Advancing genomic research on the African continent will be
cost intensive, but will also be complex, extremely challenging
and time consuming. Advances may well depend on the pace of lo-
cal communities, their willingness to effectively engage in the pro-
ject and will, unfortunately, be hampered by unstable governments
and regional conﬂicts. Weighing in the balance is the potential
beneﬁt of genomic science to improve health for the people on
the continent. Early successes will be essential to build conﬁdence
in the research to ensure support of future endeavours.
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